Avidity Biosciences, Inc.: other noncurrent assets

What this measure means

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Exact concept: us-gaap:OtherAssetsNoncurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2019-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.

Selected filing history

Related financial histories

• Avidity Biosciences, Inc.: total assets
• Avidity Biosciences, Inc.: total liabilities
• Avidity Biosciences, Inc.: stockholders equity
• Avidity Biosciences, Inc.: cash and cash equivalents
• Avidity Biosciences, Inc.: net income or loss
• Avidity Biosciences, Inc.: operating cash flow
• Avidity Biosciences, Inc.: capital expenditure payments
• Avidity Biosciences, Inc.: contract revenue excluding tax
• Avidity Biosciences, Inc.: financing cash flow
• Avidity Biosciences, Inc.: investing cash flow
• Avidity Biosciences, Inc.: retained earnings or deficit
• Avidity Biosciences, Inc.: basic weighted-average shares
• Avidity Biosciences, Inc.: diluted weighted-average shares
• Avidity Biosciences, Inc.: basic earnings per share
• Avidity Biosciences, Inc.: diluted earnings per share
• Avidity Biosciences, Inc.: net property, plant and equipment
• Avidity Biosciences, Inc.: share-based compensation expense
• Avidity Biosciences, Inc.: operating income or loss
• Avidity Biosciences, Inc.: current assets
• Avidity Biosciences, Inc.: interest expense
• Avidity Biosciences, Inc.: current liabilities
• Avidity Biosciences, Inc.: current accounts payable
• Avidity Biosciences, Inc.: net current accounts receivable
• Avidity Biosciences, Inc.: operating expenses
• Avidity Biosciences, Inc.: research and development expense
• Avidity Biosciences, Inc.: common shares outstanding
• Avidity Biosciences, Inc.: cash including restricted cash
• Avidity Biosciences, Inc.: additional paid-in capital
• Avidity Biosciences, Inc.: accumulated other comprehensive income or loss
• Avidity Biosciences, Inc.: operating lease right-of-use asset
• Avidity Biosciences, Inc.: operating lease liability
• Avidity Biosciences, Inc.: gross property, plant and equipment
• Avidity Biosciences, Inc.: accumulated depreciation on property, plant and equipment
• Avidity Biosciences, Inc.: prepaid expenses and other current assets
• Avidity Biosciences, Inc.: current contract liabilities
• Avidity Biosciences, Inc.: net deferred tax assets
• Avidity Biosciences, Inc.: pre-tax income or loss from continuing operations
• Avidity Biosciences, Inc.: profit or loss including noncontrolling interests
• Avidity Biosciences, Inc.: comprehensive income or loss
• Avidity Biosciences, Inc.: general and administrative expense
• Avidity Biosciences, Inc.: depreciation expense
• Avidity Biosciences, Inc.: other nonoperating income or expense
• Avidity Biosciences, Inc.: nonoperating income or expense
• Avidity Biosciences, Inc.: interest paid, net
• Avidity Biosciences, Inc.: proceeds from issuing common stock
• Avidity Biosciences, Inc.: operating lease payments
• Avidity Biosciences, Inc.: change in accounts payable

Inspect the source

Entity

Avidity Biosciences, Inc. / CIK 0001599901

Captured

2026-09-21T17:20:20.082Z

SEC response SHA-256

a2115d7e8f570058dad08e35568dcb84ba59f6e7e1538c5e66b8f7f7e6ea4685

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001599901.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))